Zhong Guo Zheng Quan Bao·2025-10-16 20:11Core Viewpoint - The article emphasizes the significant role of A-share listed companies in driving China's high-quality economic development through innovation, with substantial R&D investments and transformative achievements in various sectors [1][2]. Group 1: Innovation and R&D Investment - A-share listed companies have contributed over 1.88 trillion yuan in R&D, accounting for 51.96% of the national R&D expenditure, with a 48% increase in overall R&D investment since 2020 [2]. - The R&D intensity of A-share companies has risen to 2.61%, surpassing the average of EU countries, with notable contributions from companies like BYD and CATL [2]. - The emergence of innovative drugs, such as Zepzelca, showcases the global competitiveness of Chinese original research drugs, supported by significant R&D investments from companies like BeiGene [2][3]. Group 2: Technology and Industry Integration - Listed companies are pivotal in transforming scientific achievements into industrial applications, exemplified by advancements in tire technology and battery recycling [3]. - The integration of AI and digital technologies in manufacturing has led to significant efficiency improvements, with smart factories achieving notable reductions in production cycles and defect rates [5][6]. Group 3: High-end, Intelligent, and Green Transformation - Companies are focusing on high-end manufacturing to enhance brand value, as seen with LONGi Green Energy's advancements in solar technology [5]. - The shift towards intelligent manufacturing is evident, with significant investments in digital transformation across various industries, including agriculture and logistics [6][7]. - The green transformation is highlighted by the establishment of a comprehensive renewable energy industry chain, with A-share companies investing 1.3 trillion yuan in renewable projects [7]. Group 4: Global Expansion and Collaboration - A-share companies have significantly increased their overseas revenue, reaching 9.52 trillion yuan, marking a 56.58% growth since 2020 [8]. - The export of innovative products, particularly in pharmaceuticals, has seen substantial growth, indicating a shift towards higher value-added exports [9]. - Companies are adopting a collaborative approach in global markets, integrating local manufacturing and supply chain partnerships to enhance their international presence [10].